Daniel Benjamin Mark, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 2400 Pratt St, Durham, NC 27705
Phone (919) 668-8775
Email address mark0004@mc.duke.edu

Dr. Mark is a clinical cardiologist with the rank of Professor of Medicine (with tenure) as well as Vice Chief for Academic Affairs in the Division of Cardiology, Department of Medicine at Duke University Medical Center. He is also the Director of Outcomes Research at the Duke Clinical Research Institute. He has been on the full-time faculty at Duke since 1985. Prior to that he completed his cardiology fellowship at Duke, his residency and internship at the University of Virginia Hospital, and received his medical degree from Tufts University and his Master’s degree from Harvard. In 1998, he was given the honor of being elected to the American Society for Clinical Investigators and in 2002 he was honored by election to the Association of American Physicians. These organizations are the two most prestigious honor societies in academic medicine. In 2009, Dr. Mark was awarded the American College of Cardiology Distinguished Scientist Award.

Dr. Mark's major research interests include medical economics and quality of life outcomes, outcomes research, and quality of medical care. Currently, Dr. Mark is directing a number of outcomes analyses for ongoing clinical trials including PROMISE (anatomic versus functional testing for coronary artery disease, NIH), CABANA (catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation, NIH), ISCHEMIA (percutaneous coronary intervention versus optimal medical therapy for moderate-severe ischemia), and STICH (CABG +/- ventricular reconstruction versus medical therapy for ischemic heart disease, NIH). He was the principal author of the AHCPR Unstable Angina Guidelines and is a co-author of both the American College of Cardiology Guideline on Exercise Testing and their Coronary Stent Consensus Guideline. He is also the Editor of the American Heart Journal. Dr. Mark has published over 270 peer-reviewed articles, two books, and 80 book chapters. He lectures widely in the US, as well as in Canada, South America, and Europe.

Keywords: cost-effectiveness analysis, disease management, quality of life assessment, resource use.

Education and Training

  • M.D., Tufts University, 1978

Publications

Escolar, Esteban, Gervasio A. Lamas, Daniel B. Mark, Pamela Ouyang, Allan Magaziner, Robin Boineau, Ralph Miranda, et al. “Clinical Benefit of EDTA Chelation Therapy in Patients With Diabetes in the Trial to Assess Chelation Therapy (TACT).” In Circulation, Vol. 128. LIPPINCOTT WILLIAMS & WILKINS, 2013.

Scholars@Duke

Chen, Jay, George Johnson, Anne S. Hellkamp, Jill Anderson, Daniel B. Mark, Kerry L. Lee, Gust H. Bardy, and Jeanne E. Poole. “Reply: rapid rate nonsustained ventricular tachycardia found on ICD interrogation: relationship of RR-NSVT to outcomes in the SCD-HeFT trial..” J Am Coll Cardiol 62, no. 21 (November 19, 2013): 2028–29. https://doi.org/10.1016/j.jacc.2013.07.061.

PMID
23994409
Full Text

Aoukar, Pierre S., Jeanne E. Poole, George W. Johnson, Jill Anderson, Anne S. Hellkamp, Daniel B. Mark, Kerry L. Lee, and Gust H. Bardy. “No benefit of a dual coil over a single coil ICD lead: evidence from the Sudden Cardiac Death in Heart Failure Trial..” Heart Rhythm 10, no. 7 (July 2013): 970–76. https://doi.org/10.1016/j.hrthm.2013.03.046.

PMID
23562699
Full Text

Hess, Paul L., Amy Laird, Rex Edwards, Gust H. Bardy, J Thomas Bigger, Alfred E. Buxton, Arthur J. Moss, et al. “Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials..” Heart Rhythm 10, no. 6 (June 2013): 828–35. https://doi.org/10.1016/j.hrthm.2013.02.011.

PMID
23416381
Full Text

Chen, Jay, George Johnson, Anne S. Hellkamp, Jill Anderson, Daniel B. Mark, Kerry L. Lee, Gust H. Bardy, and Jeanne E. Poole. “Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial)..” J Am Coll Cardiol 61, no. 21 (May 28, 2013): 2161–68. https://doi.org/10.1016/j.jacc.2013.02.046.

PMID
23541974
Full Text

Lamas, Gervasio A., Christine Goertz, Robin Boineau, Daniel B. Mark, Theodore Rozema, Richard L. Nahin, Lauren Lindblad, et al. “Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial..” Jama 309, no. 12 (March 27, 2013): 1241–50. https://doi.org/10.1001/jama.2013.2107.

PMID
23532240
Full Text

Finlen Copeland, C Ashley, David M. Vock, Karen Pieper, Daniel B. Mark, and Scott M. Palmer. “Impact of lung transplantation on recipient quality of life: a serial, prospective, multicenter analysis through the first posttransplant year..” Chest 143, no. 3 (March 2013): 744–50. https://doi.org/10.1378/chest.12-0971.

PMID
23188377
Full Text

Mitchell, Judith E., Anne S. Hellkamp, Daniel B. Mark, Jill Anderson, George W. Johnson, Jeanne E. Poole, Kerry L. Lee, and Gust H. Bardy. “Thyroid function in heart failure and impact on mortality..” Jacc Heart Fail 1, no. 1 (February 2013): 48–55. https://doi.org/10.1016/j.jchf.2012.10.004.

PMID
24159562
Full Text

Al-Khatib, Sana M., Anne Hellkamp, Gust H. Bardy, Stephen Hammill, W Jackson Hall, Daniel B. Mark, Kevin J. Anstrom, et al. “Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials..” Jama 309, no. 1 (January 2, 2013): 55–62. https://doi.org/10.1001/jama.2012.157182.

PMID
23280225
Full Text

Pages